Welcome to SynAging SAS

Your R&D partner for in vitro and in vivo phenotypic models in WT, accelerating drug discovery for sporadic neurodegenerative diseases.

News

SynAging has new phone and fax numbers in 2017! Please amend your records accordingly. The old numbers will work until the end of 2017 only!

SynAging will be present at the following meetings in 2017:

European Brain & Behavior Society Meeting, September 8-11, Bilbao, Spain

Neuroscience R&D Technologies Conference, September 28-29, London, UK - Presentation on Sept. 29

Genesis Drug Discovery, October 11-12, Frankfurt, Germany - Presentation on Oct. 11

BIO-Europe 2017, November 6-8, Berlin, Germany

BioFIT 2017, November 28-29, Strassbourg, France, meet us at booth C4

SynAging' past meetings in 2017:

EuroTau Meeting, April 27-28, Lille, France

International Conference on Alzheimer's & Parkinson’s Diseases 2017 - Booth 14a, at the entrance of the exhibition & Posters
March 29 . – April 2., Vienna, Austria

SynAging's past meetings in 2016:

Press & Publications

Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy
www.ncbi.nlm.nih.gov/pubmed/28623233

ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer’s Disease
promisneurosciences.com/uncategorized/promis-neurosciences-designates-pmn350-second-lead-product-development-alzheimers-disease/

HUMAN TAU OLIGOMERS INDUCE NEURODEGENERATION: TAUOPATHY MODELS FOR TARGET VALIDATION AND DRUG DEVELOPMENT
Download PDF

HUMAN ALPHA-SYNUCLEIN OLIGOMERS BUT NOT 'SPREADING' FIBRILS INDUCE EARLY COGNITIVE DECLINE IN MICE
Download PDF

SynAging's human tau oligomer poster at SFN 2016
Download PDF

SynAging's alpha synuclein oligomer poster at SFN 2016
Download PDF

SynAging's Alzheimers disease poster at AAIC 2016
Download PDF

SynAging's Parkinson's disease poster at AAIC 2016
Download PDF

 

In vitro Human Models of Alzheimer´s Disease

Human iPSC-derived (HIP™) neurons from MTI-GlobalStem are seeded, differentiated and matured in 96 well plates for five weeks. The cultures contain 60% neurons and 40% astroglial cells.

Immage above: Neurons derived from human IPS cells, cultured for five weeks and stained for:MAP2 (green) for neurons, GFAP (red) for glia cells, and DAPI (blue) staining cell nuclei.

The expression of the following markers has been verified by Western Blot Analysis: β-tubulin, SNAP25, GFAP, and total tau:

Immages below: The neurons have been verified to express PSD 95 and synaptophysine in a DAPI stained background of nuclei by immunohistochemistry:

The five weeks old human neurons are treated for 24 h with SynAging’s AβO preparation (1 µM based on monomer), with or without BDNF (1.5 nM). The readout indicating neuronal health is a specific marker for neurons: an ELISA for neuron specific enolase (NSE; Oliva D, Calì L, Feo S, Giallongo A (1991). "Complete structure of the human gene encoding neuron-specific enolase.". Genomics 10 (1): 157–65):

Further read-outs can be added to this model:

  • Gene and protein expression changes by RT-qPCR, immunoblot, or ELISA
  • Protein phosphorylation
  • Validated ELISA quantification of synaptic markers: e.g. PSD95, Synaptophysin, SNAP25
  • Oxidative stress

SynAging’s in vitro human AD assay can investigate three test items, or three test item concentrations, in triplicate, per plate, with the following groups:

  • Vehicle (vehicle control)
  • AbO (negative control)
  • AbO and BDNF / humanin (positive control)
  • Test Item in vehicle control
  • Test Item in AbO

 

Please contact us to discuss your interests and requirements for this model.

Product Sheet “In vitroAD Screen on Human Neurons" Download PDF, 550 KB